May 8 – 10, 2018

Boston, MA

Speaker Faculty

Expand/Collapse

David Barbie MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute/ Harvard Medical School

Olivia Candini
Cell and Tissue Engineering R&D Manager
Rigenerand srl

Brett Hall
CEO
Asellus

Christopher Heery
CMO
Bavarian Nordic

Day Two

Thursday May 10th, 2018

09.00 | Requirements for Improved Preclinical Models for More Rapid Clinical Development in Immuno-Oncology

Cristina Bertinetti-Lapatki
Lab Head Mechanistic Safety
Roche Pharmaceuticals

Geoffrey Bartholomeusz
Associate Professor & Director, Target Identification and Validation Program
M.D.Anderson Cancer Center

Hongmin Chen
Principal Scientist
Merck & Co

Jason Ekert
Head of Complex In Vitro Models
GlaxoSmithKline

Day One

Wednesday May 9th, 2018

09.00 | Addressing Development, Validation and Automation of 3D Solid Tumor Models in Preclinical Drug Discovery

Mark Kaplan
Translational Oncology Lead
Pfizer

Day Two

Thursday May 10th, 2018

09.30 | 3D In Vitro Systems for Translational Oncology: Opportunities and Challenges

Mark Paris
Associate Director, Translational Applications
Mitra Biotech

Roger Kamm
Cecil and Ida Green Distinguished Professor of Mechanical and Biological Engineering
MIT

Shane Horman
Research Investigator III
Novartis GNF

Shawn Hingtgen
Assistant Professor
UNC Eshelman School of Pharmacy

Day One

Wednesday May 9th, 2018

08.30 | Overcoming Challenges for 3D Models in Preclinical Discovery & Assessing of Cytotoxic Effects of Oncology Drug Candidates

Bill Hastings
Investigator III, Exploratory Immuno Oncology
Novartis Institutes for Biomedical Research

Susan Kaufman
Senior Scientific Researcher
Genentech

Svetlana Sadekova
Senior Principal Scientist & Head of Translational Pathology Group
Merck & Co

Timothy Spicer
Assistant Professor - Molecular Medicine & Associate Scientific Director
Scripps Institute

Day One

Wednesday May 9th, 2018

09.30 | A Comparative Analysis of 3D Platforms in High Throughput Formats to Assess the Cytotoxic Effect of Drugs for Discovery

Eugen Dhimolea
Research Fellow, Medical Oncology
Dana-Farber Cancer Institute